智通财经网·2026-01-15 00:52Core Insights - WuXi AppTec (603259.SH, 02359) presented at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, updating on its business progress [2] - As of Q3 2025, the company has a total of 3,430 small molecule CDMO pipelines, representing 16% of the global clinical-stage new drug pipelines, with 167 projects in Phase III and commercialization [2] - The number of Phase III and commercial projects has increased from 107 in 2022 to 167, marking a growth of 56%, with corresponding revenue rising from 4.7 billion to 10.3 billion yuan, and expected to reach a new high this year [2] Industry Trends - Oral medications are rapidly replacing injectables in mainstream treatment areas due to their convenience, becoming a new focus in the pharmaceutical industry [2] - Recently, industry media Endpoints News identified "Pills" as a key term for 2025, highlighting the strong rise of this sector [2] - Oral formulations are expanding in areas such as obesity, heart disease, and inflammatory diseases, continuously capturing market share previously dominated by large molecule biologics [2]